Essential Pharma Acquires Reminyl (galantamine hydrobromide) Oral Capsules from Janssen
Shots:
- Essential Pharma has completed the acquisition of Reminyl oral capsules from Janssen Pharmaceutica to treat mild to moderately severe dementia of the Alzheimer type expanding its CNS medicines portfolio
- Through the acquisition, Essential Pharma has obtained rights to Reminyl across the EEA, Thailand, South Korea and all other current markets for the product except UK, Ireland, Japan & Latin America
- Reminyl is a cholinesterase inhibitor from the company’s CNS drug portfolio developed as a treatment of mild to moderately severe Alzheimer’s dementia
Ref: Essential Pharma | Image: Essential Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
